CLCGY:OTC-Clicks Group Ltd (USD)

COMMON STOCK | Pharmaceutical Retailers |

Last Closing

USD 42.63

Change

+0.63 (+1.50)%

Market Cap

USD 5.11B

Volume

500.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Clicks Group Limited, together with its subsidiaries, operates as a health, wellness, and beauty retailer in South Africa and internationally. It operates through two segments: Retail and Distribution. The company retails pharmacy, health, and beauty through stores, and in-store pharmacies for the middle to upper income markets under the Clicks brand name. It also offers various range of mother and baby products including baby hardware, accessories, health, foods, diapers and wipes, and baby toiletries under the Clicks Baby brand; beauty therapy, grooming, and ethnic hair care under the Sorbet brand name; diabetic clinic, travel clinic, and wounds management practice under the M-KEM brand; and naturally-inspired beauty products under The Body Shop brand name. In addition, the company involved in the wholesale and supply of pharmaceutical products to retail pharmacies, private hospitals, dispensing doctors, and retail health stores under the UPD brand. The company was formerly known as New Clicks Holdings Limited and changed its name to Clicks Group Limited in June 2009. Clicks Group Limited was founded in 1968 and is headquartered in Cape Town, South Africa.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Pharmaceutical Retailers

Symbol Name Price(Change) Market Cap
JDHIY JD Health International Inc

N/A

USD 12.16B
JDHIF JD Health International Inc

N/A

USD 9.97B
ALBHF Alibaba Health Information Tec..

N/A

USD 8.27B
RADLY Raia Drogasil SA ADR

-0.29 (-5.87%)

USD 7.74B
SHPPF Shop Apotheke Europe N.V

N/A

USD 3.23B
SAEYY Shop Apotheke Europe N.V

N/A

USD 3.16B
NOTR Nowtransit Inc

N/A

USD 0.55B
ZRSEF Zur Rose Group AG

-3.47 (-8.17%)

USD 0.54B
NVACF Nova Cannabis Inc

N/A

USD 0.08B
PNPL Pineapple Express

N/A

USD 0.01B

ETFs Containing CLCGY

N/A

Market Performance

  Market Performance vs. Industry/Classification (Pharmaceutical Retailers) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -39.87% 35% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.87% 35% F 26% F
Trailing 12 Months  
Capital Gain -34.62% 41% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -34.62% 41% F 28% F
Trailing 5 Years  
Capital Gain -39.07% 86% B+ 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.07% 86% B+ 42% F
Average Annual (5 Year Horizon)  
Capital Gain 5.08% 40% F 46% F
Dividend Return 7.10% 40% F 46% F
Total Return 2.01% 100% F 42% F
Risk Return Profile  
Volatility (Standard Deviation) 24.26% 92% A 80% B-
Risk Adjusted Return 29.25% 84% B 65% D
Market Capitalization 5.11B 81% B- 86% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector